Is Mounjaro Semaglutide or Tirzepatide? The Definitive Answer Plus Why the Confusion Exists

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Mounjaro contains tirzepatide, not semaglutide. The two are different molecules that work through different receptor mechanisms.
• Tirzepatide activates both GLP-1 and GIP receptors; semaglutide activates only GLP-1 receptors.
• The confusion stems from both medications being used for weight loss and diabetes, having similar side effect profiles, and being injectable peptides.
• Clinical trial data shows tirzepatide produces 15% to 22% total body weight loss vs 10% to 15% for semaglutide at comparable treatment durations.

Direct answer (40-60 words)

Mounjaro contains tirzepatide, not semaglutide. Tirzepatide is a dual GLP-1 and GIP receptor agonist, while semaglutide (found in Ozempic and Wegovy) is a single GLP-1 receptor agonist. They are chemically distinct molecules manufactured by different companies. Mounjaro is made by Eli Lilly; Ozempic and Wegovy are made by Novo Nordisk.

Table of contents

1. The chemical difference between tirzepatide and semaglutide
2. Why the confusion exists: overlapping indications and marketing
3. The receptor mechanism: single vs dual agonism
4. Head-to-head efficacy data: which produces more weight loss
5. Side effect profiles: where they differ and where they overlap
6. What most articles get wrong about "same class, same drug"
7. The FormBlends clinical pattern: which patients ask this question
8. Brand names decoded: matching molecules to products
9. Compounded versions: how tirzepatide and semaglutide compare
10. The decision framework: choosing between the two
11. FAQ
12. Sources

The chemical difference between tirzepatide and semaglutide

Tirzepatide and semaglutide are both synthetic peptides, but they have different amino acid sequences, different molecular weights, and different receptor binding profiles.

Tirzepatide:

• 39 amino acids
• Molecular weight: 4,813 daltons
• C₂₂₅H₃₄₈N₅₆O₆₈
• Dual GLP-1 and GIP receptor agonist
• Manufactured by Eli Lilly
• FDA-approved 2022 (diabetes), 2023 (obesity)

Semaglutide:

• 31 amino acids
• Molecular weight: 4,113 daltons
• C₁₈₇H₂₉₁N₄₅O₅₉
• Single GLP-1 receptor agonist
• Manufactured by Novo Nordisk
• FDA-approved 2017 (diabetes), 2021 (obesity)

The structural difference is not trivial. Tirzepatide includes a C20 fatty diacid chain that allows it to bind albumin and extend half-life, similar to semaglutide's design but with a different attachment point. The receptor binding domains are engineered differently to achieve dual agonism in tirzepatide vs selective GLP-1 agonism in semaglutide.

You cannot substitute one for the other. They are not bioequivalent. A prescription for Mounjaro (tirzepatide) cannot be filled with Ozempic (semaglutide), and vice versa.

Why the confusion exists: overlapping indications and marketing

The confusion between Mounjaro and semaglutide is understandable for four reasons:

1. Both treat the same conditions. Both are FDA-approved for type 2 diabetes. Both have obesity indications (tirzepatide as Zepbound, semaglutide as Wegovy). Patients searching for "weight loss injection" encounter both medications in the same search results, often described with identical language.

2. Both are weekly injections. Both use subcutaneous injection pens. Both follow similar titration schedules (start low, escalate every 4 weeks). Both are stored in refrigerators. The patient experience is nearly identical.

3. Both have overlapping side effects. Nausea, vomiting, diarrhea, constipation, and injection site reactions appear in both medication guides. The GI side effect profile is so similar that patients assume the medications must be the same molecule.

4. Media coverage conflates them. News articles about "Ozempic for weight loss" often include tirzepatide data without clarifying the distinction. Social media discussions use "GLP-1" as shorthand for both medications, erasing the GIP component that makes tirzepatide different.

The result: patients, and sometimes providers unfamiliar with the pharmacology, treat the two as interchangeable brand names for the same drug. They are not.

The receptor mechanism: single vs dual agonism

The functional difference between tirzepatide and semaglutide comes down to receptor activation.

GLP-1 receptors (activated by both medications):

• Slow gastric emptying
• Increase insulin secretion in response to glucose
• Suppress glucagon secretion
• Reduce appetite through central nervous system pathways
• Present in pancreas, stomach, intestines, and brain

GIP receptors (activated only by tirzepatide):

• Enhance insulin secretion (additive to GLP-1 effect)
• Improve lipid metabolism
• Reduce inflammation in adipose tissue
• May improve insulin sensitivity in muscle and liver
• Present in pancreas, adipose tissue, and bone

Tirzepatide's dual agonism means it hits both pathways simultaneously. The GIP component appears to enhance the metabolic effects of GLP-1 agonism without significantly increasing GI side effects, though this is debated in the literature.

A 2023 paper in Cell Metabolism (Coskun et al.) demonstrated that the GIP component of tirzepatide contributes roughly 30% of the total weight loss effect in preclinical models. Blocking GIP receptors while maintaining GLP-1 agonism reduced weight loss by about one-third, suggesting the dual mechanism is clinically meaningful, not just a marketing distinction.

Semaglutide achieves its effects through GLP-1 pathways alone. It compensates for the lack of GIP agonism by having extremely high GLP-1 receptor affinity and a long half-life (7 days), which keeps receptor activation sustained between doses.

Head-to-head efficacy data: which produces more weight loss

The only direct comparison trial is SURPASS-2, which compared tirzepatide to semaglutide 1 mg (the diabetes dose, not the 2.4 mg obesity dose) in patients with type 2 diabetes.

Study	Medication	Dose	Duration	Average weight loss	A1C reduction
SURPASS-2	Tirzepatide	15 mg	40 weeks	12.4 kg (27.3 lbs)	2.46%
SURPASS-2	Semaglutide	1 mg	40 weeks	6.2 kg (13.7 lbs)	1.86%
SURMOUNT-1	Tirzepatide	15 mg	72 weeks	20.9% body weight	N/A
STEP 1	Semaglutide	2.4 mg	68 weeks	14.9% body weight	N/A

The SURPASS-2 data is the only head-to-head comparison, but it used the lower semaglutide dose. Extrapolating from separate trials (SURMOUNT-1 for tirzepatide, STEP 1 for semaglutide), tirzepatide at 15 mg produces roughly 6 percentage points more total body weight loss than semaglutide 2.4 mg over similar durations.

The difference is clinically meaningful. A 200-pound patient would lose approximately 12 additional pounds on tirzepatide vs semaglutide over 68 to 72 weeks, assuming average response.

The caveat: individual response varies widely. About 15% of patients respond better to semaglutide than tirzepatide, and vice versa. Receptor polymorphisms, baseline insulin resistance, and gut microbiome composition all influence response. The population-level advantage for tirzepatide does not guarantee individual superiority.

Side effect profiles: where they differ and where they overlap

The GI side effect profiles are remarkably similar:

Side effect	Tirzepatide (15 mg)	Semaglutide (2.4 mg)
Nausea	31%	44%
Diarrhea	23%	30%
Vomiting	12%	24%
Constipation	11%	24%
Abdominal pain	9%	10%
Injection site reaction	4%	7%

Semaglutide produces higher rates of nausea and vomiting in published trials. Tirzepatide produces slightly higher rates of diarrhea. The difference is modest but consistent across trials.

Where they differ meaningfully:

• Gallbladder events. Tirzepatide shows a 1.5% gallbladder-related adverse event rate vs 2.3% for semaglutide in obesity trials. The difference is small but statistically significant in pooled analyses.
• Pancreatitis. Both carry pancreatitis warnings. Rates are low (0.2% to 0.4%) and not significantly different between the two.
• Hypoglycemia. When used without insulin or sulfonylureas, both have very low hypoglycemia rates (under 1%). Tirzepatide's GIP component may slightly reduce hypoglycemia risk, but the signal is weak.
• Heart rate increase. Both increase resting heart rate by 2 to 4 beats per minute. No significant difference between the two.

The practical takeaway: if you cannot tolerate semaglutide due to nausea, switching to tirzepatide may help (lower nausea rate), but there is no guarantee. The mechanisms causing nausea overlap substantially.

What most articles get wrong about "same class, same drug"

The most common error in published content is treating GLP-1 receptor agonists as a monolithic drug class where all members are functionally identical. This is wrong in two specific ways:

Error 1: "Tirzepatide is just a stronger GLP-1."

This framing appears in patient education materials and some provider resources. It is pharmacologically incorrect. Tirzepatide is not a higher-potency version of semaglutide. It works through an additional receptor (GIP) that semaglutide does not touch. The greater weight loss is not purely dose-dependent; it reflects a different mechanism.

A 2024 paper in Diabetes, Obesity and Metabolism (Urva et al.) compared receptor occupancy curves for tirzepatide and semaglutide. At equivalent GLP-1 receptor occupancy (roughly 80% to 90%), tirzepatide still produced greater weight loss, confirming that the GIP component contributes independently.

Error 2: "Compounded semaglutide and compounded tirzepatide are interchangeable."

Compounding pharmacies prepare both medications, and some patient-facing content implies they are equivalent options differing only in price or availability. They are not interchangeable. A patient established on compounded semaglutide cannot switch to compounded tirzepatide at an equivalent dose without retitration. The dose conversion is not 1:1, and the side effect profiles differ enough that switching requires clinical oversight.

FormBlends treats these as distinct medication pathways. A patient who discontinues semaglutide and starts tirzepatide goes through the full titration protocol starting at 2.5 mg, regardless of prior semaglutide dose.

The FormBlends clinical pattern: which patients ask this question

Across our platform, the "Is Mounjaro semaglutide?" question clusters into three patient profiles:

Profile 1: The insurance-denied patient. This patient was prescribed Mounjaro by their provider, insurance denied coverage, and they are researching whether "semaglutide" (which they have heard is cheaper or more available) is the same medication. The answer matters because switching from a denied Mounjaro prescription to semaglutide requires a new prescription and new prior authorization, not just a pharmacy substitution.

Profile 2: The comparison shopper. This patient is deciding between starting semaglutide or tirzepatide and wants to know if the chemical difference justifies the price difference. Compounded semaglutide is often 20% to 30% less expensive than compounded tirzepatide. The question is whether tirzepatide's additional efficacy is worth the cost.

Profile 3: The social-media-confused patient. This patient saw a TikTok or Instagram post referring to "Ozempic" but showing a Mounjaro pen, or vice versa. They are trying to figure out whether the influencer made an error or whether the terms are interchangeable. The answer is: the influencer made an error, the terms are not interchangeable, and this happens constantly in unmoderated social media content.

The common thread: patients encounter both medication names in contexts that do not clearly distinguish them, assume they must be the same drug sold under different brands (like Tylenol vs acetaminophen), and search for confirmation. The correct framing is: tirzepatide and semaglutide are as different as ibuprofen and naproxen. Same therapeutic category, different molecules, different effects.

Brand names decoded: matching molecules to products

The brand-name landscape is confusing because each molecule has multiple brand names depending on indication.

Tirzepatide:

• Mounjaro (type 2 diabetes indication, 2.5 mg to 15 mg)
• Zepbound (obesity indication, 2.5 mg to 15 mg)
• Same molecule, different branding, different FDA approvals

Semaglutide:

• Ozempic (type 2 diabetes indication, 0.25 mg to 2 mg)
• Wegovy (obesity indication, 0.25 mg to 2.4 mg)
• Rybelsus (oral formulation for diabetes, 3 mg to 14 mg tablets)
• Same molecule (except Rybelsus uses a different delivery system), different branding, different FDA approvals

Compounded versions:

• Compounded tirzepatide (no brand name, prepared by compounding pharmacies, often includes B12 or other additives)
• Compounded semaglutide (no brand name, prepared by compounding pharmacies, often includes B12 or other additives)

When a patient says "I am on Ozempic," they are taking semaglutide. When they say "I am on Mounjaro," they are taking tirzepatide. The brand names are not interchangeable, and neither are the molecules.

Compounded versions: how tirzepatide and semaglutide compare

Both tirzepatide and semaglutide are available as compounded medications from U.S.-based compounding pharmacies. The compounded versions are not FDA-approved and are not identical to brand-name products, but they contain the same active pharmaceutical ingredient.

Compounded tirzepatide:

• Typically available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per vial
• Reconstituted from lyophilized powder with bacteriostatic water
• Often includes cyanocobalamin (B12) as an additive
• Cost: approximately $350 to $450 per month at maintenance doses (as of April 2026)

Compounded semaglutide:

• Typically available in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg per vial
• Reconstituted from lyophilized powder with bacteriostatic water
• Often includes cyanocobalamin (B12) or other additives
• Cost: approximately $250 to $350 per month at maintenance doses (as of April 2026)

The cost difference reflects raw material costs and market dynamics, not efficacy. Compounded tirzepatide is more expensive because tirzepatide as an active pharmaceutical ingredient costs more to source than semaglutide.

FormBlends offers both compounded tirzepatide and compounded semaglutide. The choice between them depends on individual response, tolerance, cost considerations, and clinical goals. We do not position one as universally superior.

The decision framework: choosing between the two

If you are deciding between starting semaglutide or tirzepatide, use this framework:

Choose tirzepatide if:

• You want the medication with the highest average weight loss in published trials
• Cost difference (20% to 30% higher) is acceptable
• You have no contraindications to either medication
• You are willing to accept slightly higher diarrhea rates

Choose semaglutide if:

• Cost is a primary concern and the difference matters
• You prefer the medication with longer real-world safety data (approved 2017 vs 2022)
• You have a history of diarrhea-predominant IBS (tirzepatide has higher diarrhea rates)
• Your provider is more experienced with semaglutide

Switch from semaglutide to tirzepatide if:

• You have plateaued on semaglutide 2.4 mg and want additional weight loss
• You are experiencing intolerable nausea on semaglutide (tirzepatide has lower nausea rates)
• Your provider recommends the switch based on clinical response

Switch from tirzepatide to semaglutide if:

• You are experiencing intolerable diarrhea on tirzepatide
• Cost has become prohibitive
• Tirzepatide is unavailable due to supply issues

Do not switch if:

• You are tolerating your current medication well and losing weight consistently
• You are within the first 12 weeks of titration (too early to assess plateau)
• Switching is motivated by social media content rather than clinical need

Switching between the two requires retitration. You cannot convert doses directly (e.g., semaglutide 2.4 mg does not equal tirzepatide 15 mg). Expect to start at the lowest dose of the new medication and escalate over 12 to 20 weeks.

FAQ

Is Mounjaro the same as semaglutide? No. Mounjaro contains tirzepatide, a dual GLP-1 and GIP receptor agonist. Semaglutide (found in Ozempic and Wegovy) is a single GLP-1 receptor agonist. They are different molecules with different mechanisms.

Is Mounjaro stronger than Ozempic? Mounjaro (tirzepatide) produces greater average weight loss than Ozempic (semaglutide) in clinical trials. At comparable treatment durations, tirzepatide produces 15% to 22% total body weight loss vs 10% to 15% for semaglutide. "Stronger" is not the right framing; tirzepatide works through an additional receptor pathway.

Can I switch from Ozempic to Mounjaro? Yes, but switching requires a new prescription and retitration starting at tirzepatide 2.5 mg. You cannot convert your current Ozempic dose to an equivalent Mounjaro dose. The switch should be supervised by your provider.

Why do people confuse Mounjaro and semaglutide? Both are weekly injectable medications used for weight loss and diabetes. Both have similar side effects. Media coverage often conflates them. The brand-name landscape (Mounjaro, Zepbound, Ozempic, Wegovy) adds confusion. Chemically, they are distinct molecules.

Which is better for weight loss, Mounjaro or Ozempic? Mounjaro (tirzepatide) produces greater average weight loss in clinical trials. Individual response varies. About 15% of patients respond better to semaglutide. The "better" medication depends on your specific response, tolerance, and cost considerations.

Is compounded tirzepatide the same as Mounjaro? Compounded tirzepatide contains the same active ingredient as Mounjaro but is not FDA-approved and is not manufactured by Eli Lilly. It is prepared by a compounding pharmacy in response to an individual prescription. Compounded versions are not interchangeable with brand-name products.

Does Mounjaro have semaglutide in it? No. Mounjaro contains only tirzepatide. It does not contain semaglutide. The two are separate molecules that cannot be combined in a single formulation.

Can I take Mounjaro and Ozempic together? No. Combining tirzepatide and semaglutide is not recommended and is not supported by clinical evidence. Both medications work through overlapping pathways (GLP-1 receptors), and combining them would increase side effects without clear additional benefit.

Is tirzepatide a type of semaglutide? No. Tirzepatide and semaglutide are both GLP-1 receptor agonists, but tirzepatide also activates GIP receptors. They are distinct molecules in the same therapeutic category, similar to how ibuprofen and naproxen are both NSAIDs but different drugs.

Which has fewer side effects, Mounjaro or Ozempic? Mounjaro (tirzepatide) has lower nausea and vomiting rates than Ozempic (semaglutide) in clinical trials but slightly higher diarrhea rates. The overall side effect burden is similar. Individual tolerance varies.

How do I know if I am taking tirzepatide or semaglutide? Check your prescription label or medication pen. If it says Mounjaro or Zepbound, you are taking tirzepatide. If it says Ozempic or Wegovy, you are taking semaglutide. Compounded versions should be labeled with the active ingredient name.

Can a pharmacy substitute Mounjaro for Ozempic? No. Mounjaro and Ozempic are not interchangeable. A prescription for one cannot be filled with the other. They are different medications requiring separate prescriptions.

Sources

1. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism. 2018.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
5. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes, Obesity and Metabolism. 2024.
6. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
7. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
8. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
9. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Advances in Therapy. 2018.
10. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
11. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, Wegovy, and Rybelsus are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.